A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.
暂无分享,去创建一个
H. Fine | P. Albert | J. Butman | S. Kotliarova | L. Musib | T. Kreisl | L. Kim | D. Thornton
[1] S. Pastorino,et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. , 2008, Cancer research.
[2] W. Mason,et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study , 2008 .
[3] Timothy F Cloughesy,et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.
[4] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Vose,et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Weller,et al. Synergistic antiglioma activity of radiotherapy and enzastaurin , 2007, Annals of neurology.
[8] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[9] R. Herbst,et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Campbell,et al. The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts , 2005 .
[11] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[12] B. Teicher,et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice , 2004, Cancer Chemotherapy and Pharmacology.
[13] Beverly A. Teicher,et al. Antiangiogenic effects of a protein kinase Cβ-selective small molecule , 2001, Cancer Chemotherapy and Pharmacology.
[14] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. von Deimling,et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors , 1997, Acta Neuropathologica.
[16] K. Plate,et al. Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible In vivo regulatory mechanisms , 1994, International journal of cancer.
[17] R. Hellman,et al. Venous Thromboembolism and High Grade Gliomas , 1993, Thrombosis and Haemostasis.
[18] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[20] D. Norman,et al. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. , 1977, Journal of neurosurgery.